Early results from tests for a coronavirus vaccine being developed by the University of Oxford, in collaboration with AstraZeneca Plc AZN.L , show it produces a robust immune response in elderly people, the group at highest risk - Reuters reports quoting Financial Times.
It has been discovered that the vaccine triggers protective antibodies and T-cells in older age groups, the newspaper said on ft.com, citing two people familiar with the finding, encouraging researchers as they seek evidence that it will spare those in later life from serious illness or death from the virus.
But, according to Reuters, the FT cautioned that positive immunogenicity tests do not guarantee that the vaccine will ultimately prove safe and effective in older people. AstraZeneca, which is developing the vaccine with Oxford University researchers, is seen as a frontrunner in the race to produce a vaccine to protect against COVID-19.
